Ubs Group Ag Tricida, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$0.14 - $12.49 $38,165 - $3.4 Million	272,613 Added 272613.0%	272,713 $40,000
Q2 2022 Aug 10, 2022	SELL	$7.31 - $11.85 $285 - $462	-39 Reduced 28.06%	100 $1,000
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $286 - $414	39 Added 39.0%	139 $1,000
Q4 2021 Feb 14, 2022	SELL	$4.19 - $9.56 $762 - $1,739	-182 Reduced 64.54%	100 $1,000
Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $601 - $784	-169 Reduced 37.47%	282 $1,000
Q2 2021 Aug 13, 2021	SELL	$3.95 - $5.41 $10,708 - $14,666	-2,711 Reduced 85.74%	451 $2,000
Q1 2021 May 12, 2021	SELL	$4.52 - $7.8 $15,883 - $27,409	-3,514 Reduced 52.64%	3,162 $17,000
Q4 2020 Feb 11, 2021	SELL	$4.37 - $9.46 $244,632 - $529,570	-55,980 Reduced 89.34%	6,676 $47,000
Q3 2020 Nov 12, 2020	BUY	$8.56 - $26.93 $9,895 - $31,131	1,156 Added 1.88%	62,656 $567,000
Q2 2020 Jul 31, 2020	BUY	$21.21 - $31.55 $246,587 - $366,800	11,626 Added 23.31%	61,500 $1.69 Million
Q1 2020 May 01, 2020	BUY	$18.43 - $38.04 $173,444 - $357,994	9,411 Added 23.26%	49,874 $1.1 Million
Q4 2019 Feb 14, 2020	SELL	$29.6 - $43.71 $70,448 - $104,029	-2,380 Reduced 5.56%	40,463 $1.53 Million
Q3 2019 Nov 14, 2019	BUY	$29.87 - $42.22 $562,720 - $795,382	18,839 Added 78.48%	42,843 $1.32 Million
Q2 2019 Aug 14, 2019	BUY	$31.16 - $39.46 $724,376 - $917,326	23,247 Added 3070.94%	24,004 $947,000
Q1 2019 May 14, 2019	BUY	$19.96 - $38.62 $13,193 - $25,527	661 Added 688.54%	757 $29,000
Q4 2018 Feb 14, 2019	SELL	$23.57 - $32.33 $76,791 - $105,331	-3,258 Reduced 97.14%	96 $2,000
Q3 2018 Nov 14, 2018	BUY	$22.5 - $39.35 $75,465 - $131,979	3,354 New	3,354 $102,000

Others Institutions Holding TCDA

# of Institutions

Shares Held

30K

Call Options Held

124K

Put Options Held

46.5K

View Full List

About Tricida, Inc.

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

More about TCDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account